Open | - |
Close | - |
Volume / Avg. | 4.740K / 538.629K |
Day Range | - - - |
52 Wk Range | 119.760 - 322.670 |
Market Cap | $5.426B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 58 |
Short Interest | 20.43% |
Days to Cover | 4.02 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) through any online brokerage.
Other companies in Madrigal Pharmaceuticals’s space includes: Immunovant (NASDAQ:IMVT), Exact Sciences (NASDAQ:EXAS), Ionis Pharmaceuticals (NASDAQ:IONS), Cerevel Therapeutics Hldg (NASDAQ:CERE) and Roivant Sciences (NASDAQ:ROIV).
The latest price target for Madrigal Pharmaceuticals (NASDAQ: MDGL) was reported by UBS on Friday, March 15, 2024. The analyst firm set a price target for 410.00 expecting MDGL to rise to within 12 months (a possible 50.35% upside). 29 analyst firms have reported ratings in the last year.
The stock price for Madrigal Pharmaceuticals (NASDAQ: MDGL) is $272.69 last updated Today at March 19, 2024 at 7:25 AM EDT.
There are no upcoming dividends for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 7, 2024.
There is no upcoming split for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.